AU7077596A - Antisense oligonucleotide chemotherapy for benign hyperplasiaor cancer of the prostate - Google Patents

Antisense oligonucleotide chemotherapy for benign hyperplasiaor cancer of the prostate

Info

Publication number
AU7077596A
AU7077596A AU70775/96A AU7077596A AU7077596A AU 7077596 A AU7077596 A AU 7077596A AU 70775/96 A AU70775/96 A AU 70775/96A AU 7077596 A AU7077596 A AU 7077596A AU 7077596 A AU7077596 A AU 7077596A
Authority
AU
Australia
Prior art keywords
hyperplasiaor
benign
chemotherapy
prostate
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU70775/96A
Other languages
English (en)
Inventor
Paul A. Zamecnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Massachusetts UMass
Original Assignee
Worcester Foundation for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Worcester Foundation for Biomedical Research filed Critical Worcester Foundation for Biomedical Research
Publication of AU7077596A publication Critical patent/AU7077596A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11012—Linoleate 13S-lipoxygenase (1.13.11.12)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU70775/96A 1995-09-20 1996-09-20 Antisense oligonucleotide chemotherapy for benign hyperplasiaor cancer of the prostate Abandoned AU7077596A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US404495P 1995-09-20 1995-09-20
US004044 1995-09-20
PCT/US1996/015123 WO1997011172A1 (fr) 1995-09-20 1996-09-20 Chimiotherapie par les oligonucleotides antisens de l'hyperplasie ou du cancer de la prostate

Publications (1)

Publication Number Publication Date
AU7077596A true AU7077596A (en) 1997-04-09

Family

ID=21708853

Family Applications (1)

Application Number Title Priority Date Filing Date
AU70775/96A Abandoned AU7077596A (en) 1995-09-20 1996-09-20 Antisense oligonucleotide chemotherapy for benign hyperplasiaor cancer of the prostate

Country Status (4)

Country Link
EP (1) EP0856052A1 (fr)
AU (1) AU7077596A (fr)
CA (1) CA2232390A1 (fr)
WO (1) WO1997011172A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100444A (en) * 1997-02-11 2000-08-08 University Of Rochester Medical Center Prostate specific regulatory nucleic acid sequences and transgenic non-human animals expressing prostate specific antigen
JP2002516261A (ja) * 1998-05-22 2002-06-04 エンターメッド インコーポレイテッド セリンプロテアーゼを利用して内皮細胞増殖を阻害し血管新生を調節するための組成物と方法
US6413513B1 (en) 1998-05-22 2002-07-02 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108367A0 (en) * 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
EP0652014A1 (fr) * 1993-11-10 1995-05-10 National Institute Of Immunology Traitement d'hypertrophie prostatique
US6468981B1 (en) * 1994-07-29 2002-10-22 Emory University Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors

Also Published As

Publication number Publication date
CA2232390A1 (fr) 1997-03-27
WO1997011172A1 (fr) 1997-03-27
EP0856052A1 (fr) 1998-08-05

Similar Documents

Publication Publication Date Title
AU5089799A (en) Drug complex for treatment of metastatic prostate cancer
AU1958897A (en) Egf-genistein conjugates for the treatment of cancer
AU7366296A (en) Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
AU3222795A (en) Antitumor antisense oligonucleotides
EP1176964B8 (fr) Utilisation du compose et743 pour le traitement du cancer
AU1344400A (en) Inflammation-associated genes
AU4823599A (en) Prostate cancer-associated genes
AU2991299A (en) Monoterpenoid derivatives for treatment of cancer
AU5005697A (en) Methods of preventing breast cancer
AU6229098A (en) Cancer-associated genes
AU5462699A (en) Prostate derived ets factor
AU6537798A (en) Targeted cytolysis of cancer cells
AU7077596A (en) Antisense oligonucleotide chemotherapy for benign hyperplasiaor cancer of the prostate
AU9018598A (en) Prognostic compositions for prostate cancer and methods of use thereof
AU2506499A (en) Cea/nca-based differentiation cancer therapy
GB9828840D0 (en) Prostate cancer associated genes and their products
AUPO492397A0 (en) Prostate specific promoters
AU4984696A (en) Capl-specific oligonucleotides and methods of inhibiting metastatic cancer
AU4417996A (en) Treatment of prostate cancer
AU7936898A (en) Vectors for treating cancer
AU4644297A (en) Reversal of cancer phenotype by inhibiting expression of prostate tumor inducing gene
AU3370095A (en) Methods of inhibiting endometrial cancer
ZA961564B (en) Methods of inhibiting ovarian cancer.
AU5372998A (en) Antisense oligonucleotides specific for cdk4
AU5316099A (en) Prostate cancer assays and related methods